RO8191 (CDM-3008, RO4948191), an imidazonaphthyridine compound, is an orally active and potent agonist of interferon (IFN) receptor. RO8191 binds directly to the IFNα/β receptor 2 (IFNAR2), activating IFN-stimulated genes (ISGs) expression and the phosphorylation of JAK/STAT signaling.

RO8191 (CDM-3008, RO4948191), an imidazonaphthyridine compound, is an orally active and potent agonist of interferon (IFN) receptor. RO8191 binds directly to the IFNα/β receptor 2 (IFNAR2), activating IFN-stimulated genes (ISGs) expression and the phosphorylation of JAK/STAT signaling.

IMP-1088 is a potent dual inhibitor of human N-myristoyltransferases NMT1 and NMT2, with an IC50 of

IMP-1088 is a potent dual inhibitor of human N-myristoyltransferases NMT1 and NMT2, with an IC50 of

NSC 617145 is an inhibitor of WRN helicase activity in vitro with an IC50 of 230 nM and also suppresses WRN ATPase activity in a dose-dependent manner.

NSC 617145 is an inhibitor of WRN helicase activity in vitro with an IC50 of 230 nM and also suppresses WRN ATPase activity in a dose-dependent manner.

BRD-6929 is an inhibitor of histone deacetylase 1 (HDAC1) and HDAC2 with an IC50s of 0.04 µM and 0.1 µM, respectively. It exhibits antiproliferative activities against a human cancer cell line (HCT116) and in human mammary epithelial cells (HMEC).

BRD-6929 is an inhibitor of histone deacetylase 1 (HDAC1) and HDAC2 with an IC50s of 0.04 µM and 0.1 µM, respectively. It exhibits antiproliferative activities against a human cancer cell line (HCT116) and in human mammary epithelial cells (HMEC).

Soticlestat (TAK-935, OV935) is a potent, selective, and orally active inhibitor of Cholesterol 24-hydroxylase (CH24H). It may have therapeutic potential for diseases associated with neural hyperexcitation and severe epilepsy syndrome.

LDN-27219 is a potent, reversible, slow-binding inhibitor of Tissue transglutaminase (TGase), which exhibits IC50 of 0.6 μM against human hTGase. It likely binds at the GTP-binding or regulatory site rather than the enzyme’s active site. It lowers blood pressure and improves endothelium-dependent vasodilation in resistance arteries in an age-dependent manner.